The GEO Group (GEO) – Another Facility Sale; $500M ASR Planned


Wednesday, November 18, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Sale. As anticipated, The GEO Group announced the sale of its 1,635-bed Northwest ICE Processing Center to the Department of Homeland Security for $453 million, or $277,064 per bed. After taxes, transaction fees, and expenses, GEO expects to receive approximately $340 million in net proceeds.

Ongoing Management. Significantly, we expect GEO to continue to provide management services to the facility under the new 10-year management contract that goes through October 27, 2036. Although we believe there could be some changes to the contract given the change in ownership, we would expect GEO to retain the majority of the economics related to the contract.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Tectonic Metals Inc. (TETOF) – Tectonic Completes Record Drill Program at Flat


Wednesday, November 18, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Record Drilling Program Completed. Tectonic Metals completed its largest exploration program to date at the Flat Gold Project in southwestern Alaska, drilling approximately 31,000 meters in 170 holes during 2026, a 70% increase in meters drilled year over year. The program focused on expanding and defining gold mineralization at Chicken Mountain, advancing regional discoveries, and generating technical data to support upcoming resource and economic studies.

Chicken Mountain Expansion Supports Resource Development. Drilling has defined a mineralized footprint extending approximately 3.3 kilometers along strike, 700 meters in width, and 300 meters vertically, with mineralization remaining open in all directions. Higher-grade intersections at Alpha Bowl and the Adit Zone provide potential opportunities for starter-pit development, while newly identified hydrothermal breccias expand the geological understanding of the system. Approximately 50,000 meters of cumulative drilling are expected to support the maiden mineral resource estimate targeted for the first quarter of 2027.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NanoViricides (NNVC) – 3Q26 Reported With Clinical Progress Review


Wednesday, November 18, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

NV-387 Began Two-Phase 2 Trials During 3Q26. NanoViricides reported a 3Q26 loss of $5.7 million, or $(0.23) per share. The increase over previous quarters was largely due to increased R&D expenses for the two Phase 2a trials that began testing NV-387 for Ebola and Mpox in the Democratic Republic of Congo (DRC). These trials are the most advanced testing of its effectiveness as an antiviral agent.

Ebola Phase 2a Trial Began In September. The Phase 2a trial testing NV-387 for treating Ebola Bundibugyo Virus (BDBV) disease began enrollment in late September 2026. As discussed in our Research Note on October 15, patients will receive NV-387 chewable solids (gummies) for 6 days, then be evaluated to determine whether the disease has stabilized or improved. Treatment may be continued for an additional 3 days, up to 12 days total.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – Phase 2 Update Shows Continued Efficacy


Wednesday, November 18, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 2 THIO-101 Part C Data Updated. MAIA announced updated disease control rate (DCR) data for patients in Part C of the Phase 2 THIO-101 trial. This three-part trial tests ateganosine (previously THIO) in combination with cemiplimab (Libtayo, an anti-PD-1 checkpoint inhibitor from Regeneron) as third-line treatment for non-small cell lung cancer. Enrollment in Part C was completed in October 2026.

Additional Patients Show Continued Disease Control Rate. The data show that patients treated with ateganosine had a Disease Control Rate (DCR) of 88%, based on 38 of 43 patients, after at least one post-treatment tumor scan. This shows continued efficacy as more patients reach the first evaluation point. As discussed in our Research Note on July 9, the first group of patients after one tumor scan had a DCR of 90.5% (19 out of 21 patients). This compares with published studies reporting rates of 25% to 35% for standard chemotherapy.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Lucky Strike Entertainment (LUCK) – A Lucky Strike For Shareholders?


Wednesday, November 18, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Take-Private Proposal. Lucky Strike Entertainment’s founder, Chairman, and CEO, Thomas Shannon, submitted a non-binding proposal to acquire the company’s publicly held Class A shares for $4.35 per share. Shannon cited unfavorable investor sentiment, limited institutional participation, and public-company costs as reasons for his proposal, arguing that private ownership would give greater flexibility to reposition the business.

Transaction Conditions. The proposal would require approval from Lucky Strike’s Board of Directors, an independent special committee, and a majority of Class A shareholders unaffiliated with Shannon. The transaction would also require mutually acceptable definitive agreements. These conditions provide independent directors and minority shareholders with an opportunity to evaluate the proposal before any transaction can proceed.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Greenwich LifeSciences, Inc. (GLSI) – Abstracts Accepted For Presentation At SABCS


Wednesday, November 18, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Two Abstracts Accepted For Breast Cancer Conference. Greenwich LifeSciences announced that two abstracts have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), a highly regarded meeting dedicated to breast cancer research and treatment. The presentations are scheduled for December 9, 2026.

Abstracts To Be Released By The Conference Sponsors. The abstracts have not yet been released to the public by the SABCS. Scientific meeting abstracts are typically released shortly before the event so that those attending can choose which presentations to attend. Greenwich LifeSciences plans to post the abstracts on its website when available.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Solid Third Quarter Results; Increasing 2027 Estimates


Wednesday, November 18, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter Financial Results. Euroseas reported third-quarter 2026 net revenue of $54.1 million, down 5.0% year over year and below our estimate of $55.5 million. Adj. EBITDA declined 1.3% to $38.3 million but was above our $35.5 million estimate. Adj. net income increased 3.9% to $30.7 million, exceeding our $27.1 million estimate, while adj. EPS increased to $4.37 compared with $4.23 during the prior-year period and our estimate of $3.84. The average time charter equivalent (TCE) rate of $29,705 per day was slightly below our $29,857 forecast.

Updating Estimates. We have adjusted our 2026 revenue, adj. EBITDA and EPS estimates to $218.0 million, $145.2 million, and $16.37, respectively, from $219.3 million, $143.0 million, and $15.87. We now forecast 2027 revenue, adj. EBITDA, and adj. EPS of $240.0 million, $166.1 million, and $18.73, respectively, from $231.8 million, $162.6 million, and $18.00. Our 2027 estimates reflect higher average TCE rates.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bimergen Energy (BESS) – Project Monetization Continues with Frontier/Cerberus Projects


Wednesday, November 18, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter Results. Bimergen reported third-quarter 2026 revenue of $3.0 million compared with no revenue in the prior-year period. Gross profit totaled $0.7 million, while the operating loss narrowed to $1.2 million from $1.8 million. Net income improved to $2.4 million, or $0.33 per diluted share, compared with a loss of $1.8 million, or $0.47 per share. Results included a $3.6 million noncash gain associated with the valuation of the company’s 7.5% economic interest related to two of the Frontier/Cerberus projects that transferred to Bimergen in 2Q. The $3.6 million noncash gain was reported within other income. The company reported $3.0 million of adjusted EBITDA.

Updating Estimates. We are revising our 4Q 2026 revenue, adjusted EBITDA, and EPS estimates from $5.0 million, ($1.9 million), and ($0.45) to $8.7 million, ($0.5 million), and ($0.24). These revisions primarily reflect the anticipated recognition of development fees associated with five 9.9 MW projects, which we previously expected to occur in the third quarter.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Anthropic IPO Could Become One of the Largest in History as AI Investor Demand Grows

Anthropic, the artificial intelligence company behind the Claude family of AI models, is preparing for a highly anticipated stock market debut that could become one of the largest initial public offerings in history. The company is expected to finalize its IPO pricing on November 18, with shares scheduled to begin trading on the Nasdaq on November 19 under the ticker symbol ANT.

The offering represents a major milestone for the rapidly expanding artificial intelligence industry and could renew interest in initial public offerings, providing public market investors with an opportunity to invest directly in one of the leading developers of advanced AI models.

According to Anthropic’s latest Securities and Exchange Commission filing, the company plans to offer 825 million Class A shares at an indicated price range of $70 to $78 per share.

At the upper end of that range, the offering would raise approximately $64.35 billion before underwriting expenses, including shares sold by existing stockholders. Reports suggest strong institutional demand could push the final offering price above the initial range.

Such an outcome would make Anthropic’s debut a significant test of investor appetite for AI companies at a time when questions surrounding valuations, infrastructure spending, and long-term profitability continue to influence technology stocks.

Anthropic has emerged as a major competitor in the generative AI market, developing large language models and enterprise-focused applications through its Claude platform.

Its products compete in a rapidly growing market that includes OpenAI, Google, and other technology companies investing heavily in artificial intelligence.

Enterprise adoption has become an important growth driver as businesses increasingly incorporate AI into software development, customer support, data analysis, and other operational processes.

Anthropic’s Claude Code platform, which supports software development and programming workflows, has attracted particular attention as companies seek productivity improvements through AI-powered tools.

The company’s financial disclosures illustrate both the opportunities and challenges associated with rapid expansion.

Anthropic reported approximately $33.24 billion in revenue during the first nine months of 2026, reflecting extraordinary growth from the previous year.

However, the company also reported substantial accounting losses, highlighting the complexity of evaluating businesses that are expanding quickly while requiring significant investment in computing infrastructure and model development.

For investors, the central question is whether Anthropic can translate its expanding commercial adoption into sustainable long-term profitability. For investors evaluating newly public companies, understanding the valuation assumptions behind growth projections can be just as important as the company’s current financial performance.

Artificial intelligence companies face considerable costs associated with computing capacity, data centers, research personnel, and the development of increasingly sophisticated models.

These expenses create opportunities for businesses throughout the broader AI infrastructure ecosystem, including semiconductor manufacturers, networking providers, power equipment suppliers, and specialized industrial companies.

The IPO could also influence how investors value other companies participating in the artificial intelligence economy.

A successful public debut may strengthen confidence in AI-related growth opportunities and encourage additional technology companies to consider public listings.

Conversely, concerns about Anthropic’s valuation or its ability to generate future profits could reinforce investor caution toward businesses whose market valuations depend heavily on projected growth.

The offering also introduces corporate governance considerations. Anthropic operates as a public benefit corporation, with a governance structure intended to balance financial objectives with its stated commitment to responsible AI development.

Prospective shareholders will need to evaluate the company’s financial prospects alongside its voting structure, competitive position, and significant capital requirements.

For the broader stock market, Anthropic’s debut arrives at an important moment for the artificial intelligence investment cycle.

Investors have already committed substantial capital to companies developing chips, data centers, cloud infrastructure, and AI applications. Anthropic’s public offering provides another opportunity to assess whether expectations for the industry’s growth can support increasingly ambitious valuations.

As trading approaches, attention will turn to the final offering price, investor allocations, and how shares perform once they begin trading.

Regardless of its initial market performance, Anthropic’s IPO could become an important benchmark for future AI listings and the market’s willingness to finance the next generation of artificial intelligence companies.

What Is an IPO? Understanding How Companies Go Public and What Investors Should Know

An initial public offering, commonly known as an IPO, marks a significant milestone in a company’s development. By offering shares to public investors for the first time, a privately held business can access capital markets, expand its shareholder base, and create new opportunities for future growth.

For investors, IPOs provide access to companies entering the public markets, often during periods of expansion or transformation. However, understanding how an IPO works, how shares are valued, and what risks accompany a new listing is essential when evaluating these opportunities.

What Is an Initial Public Offering?

An IPO is the process through which a privately held company offers shares of its stock to the public for the first time.

Before an IPO, ownership is typically concentrated among founders, employees, venture capital firms, private equity investors, and other private shareholders.

Going public allows a company to raise capital by selling newly issued shares. Existing shareholders may also sell a portion of their holdings through the offering.

Companies pursue IPOs for several reasons, including funding expansion, investing in research and development, reducing debt, and increasing their visibility among institutional investors.

An IPO also establishes a publicly traded market for the company’s shares, although liquidity and trading activity can vary significantly after listing.

How Does the IPO Process Work?

The IPO process generally begins when a company selects investment banks to help manage the offering.

These banks, known as underwriters, assist with valuation, regulatory documentation, marketing, and distributing shares to investors.

In the United States, companies generally file a registration statement, commonly Form S-1, with the Securities and Exchange Commission.

The filing provides important information about the business, including financial statements, operating performance, management, potential risks, and how offering proceeds may be used.

Companies typically conduct a roadshow to present their investment case to institutional investors and assess demand.

Based on investor interest and market conditions, the company and its underwriters establish a final offering price.

Once the offering is completed and shares begin trading on an exchange such as the Nasdaq or New York Stock Exchange, investors can buy and sell the stock through brokerage accounts.

How Are IPO Shares Priced?

IPO pricing involves evaluating a company’s financial performance, growth prospects, competitive position, and comparable publicly traded businesses.

Underwriters may use valuation methods such as revenue multiples, earnings multiples, and discounted cash flow analysis.

Investor demand also influences the final offering price.

For example, a company may initially propose an IPO price range of $20 to $24 per share. Strong demand could result in pricing near or above that range, while weaker interest could lead to a lower offering price.

Importantly, the IPO offering price is not necessarily the same as the price investors pay once trading begins.

A newly listed stock can open significantly above or below its offering price, depending on market demand.

What Are the Potential Benefits of Investing in IPOs?

IPOs can provide exposure to companies entering new stages of growth.

Some businesses use public-market funding to expand operations, introduce products, acquire competitors, or enter new markets.

For investors, IPOs may also offer opportunities to participate in emerging industries or innovative business models before those companies become widely established.

However, a company’s growth potential should be evaluated alongside its valuation, profitability, financial condition, and competitive environment.

A promising business does not automatically represent an attractive investment at every share price.

What Are the Risks of IPO Investing?

Newly public companies can experience substantial share-price volatility, particularly during their initial trading sessions.

Limited public trading history can make it difficult to assess how a stock may respond to changing market conditions.

Some IPO companies are not yet profitable and may require additional financing to support operations.

Other risks include aggressive valuations, shareholder dilution, competitive pressures, and uncertainty surrounding financial forecasts.

Investors should also consider lockup agreements, which may temporarily restrict certain existing shareholders from selling stock. The expiration of these restrictions can increase the number of shares available for trading.

Reviewing the company’s prospectus and financial disclosures can help investors better understand these potential risks.

Why Do IPOs Matter to the Broader Stock Market?

IPO activity can provide insight into investor confidence and the overall environment for raising capital.

Strong demand for new listings may indicate increased willingness to invest in growing businesses, while weaker activity can reflect concerns about valuations, interest rates, or economic uncertainty.

IPOs are also important for smaller companies seeking access to capital.

For emerging businesses, entering the public markets can provide additional financing opportunities, greater visibility, and a broader investor base.

Platforms such as Channelchek, which provides access to equity research published by Noble Capital Markets, company profiles, and financial news, can help investors evaluate publicly traded businesses and follow developments across the small-cap and microcap markets.

Ultimately, understanding how IPOs work allows investors to look beyond the excitement surrounding a market debut and focus on the fundamentals that may influence a company’s long-term performance.

This article is for informational and educational purposes only and does not constitute personalized investment advice.

Beyond the Price Target: How to Evaluate Equity Research Reports

Equity research plays an important role in helping investors evaluate publicly traded companies, identify potential opportunities, and assess investment risks. While analyst ratings and price targets often attract the most attention, the real value of an equity research report lies in the financial analysis, valuation assumptions, and investment thesis supporting those conclusions.

For investors navigating today’s increasingly complex markets, understanding how to interpret equity research can provide valuable perspective on a company’s financial health, competitive positioning, and long-term growth potential. This is particularly relevant in the small-cap and microcap markets, where companies often receive less institutional coverage than their larger counterparts.

Looking Beyond Analyst Ratings

Equity research reports typically begin with an investment thesis outlining the analyst’s expectations for a company’s future performance.

Ratings such as Outperform, Market Perform, and Underperform summarize those expectations, although definitions vary among research providers.

An Outperform rating generally indicates that an analyst expects a stock to perform better than a specified benchmark or peer group. However, a favorable rating does not guarantee positive returns, and investors should examine the assumptions supporting the recommendation.

Price targets offer another reference point. A stock trading at $10 with a $14 price target implies 40% potential price appreciation, but that estimate depends on projected financial performance, valuation multiples, and market conditions.

Rather than focusing exclusively on potential upside, investors should consider what developments must occur for the analyst’s target to be realized.

Evaluating the Financial Fundamentals

Financial performance provides the foundation for most equity research conclusions.

Revenue growth can indicate expanding demand or market share, while earnings per share (EPS) helps investors evaluate profitability. EBITDA, or earnings before interest, taxes, depreciation, and amortization, is commonly used to compare operating performance across companies.

However, strong reported earnings do not always translate into healthy cash generation.

Operating cash flow and free cash flow can provide additional insight into a company’s ability to fund operations, invest in growth, and manage financial obligations.

Debt levels and liquidity are equally important, particularly for smaller companies that may face higher borrowing costs or limited access to capital.

Investors should examine whether projected improvements in revenue and profitability are supported by historical performance, realistic assumptions, and sustainable business conditions.

Understanding Valuation and Growth Catalysts

Equity research analysts use various valuation methodologies to estimate a company’s potential worth.

Comparable company analysis evaluates financial multiples, such as price-to-earnings or enterprise value-to-EBITDA, relative to similar businesses.

Discounted cash flow analysis estimates the present value of expected future cash flows, incorporating assumptions about growth, profitability, and the cost of capital.

Because these models depend on forecasts, changes in underlying assumptions can significantly affect valuation estimates.

Research reports also identify potential catalysts that could influence future performance.

These may include new product launches, major contracts, regulatory approvals, acquisitions, or expansion into new markets.

For small-cap companies, individual developments can have a particularly meaningful impact on financial results and investor sentiment.

However, investors should distinguish between anticipated catalysts and developments already reflected in a company’s share price.

Assessing Risks and Research Assumptions

A comprehensive equity research report should examine potential risks alongside growth opportunities.

Competitive pressures, customer concentration, regulatory changes, financing requirements, and shareholder dilution can all affect a company’s investment outlook.

Investors should also review research disclosures, including rating methodologies and potential conflicts of interest.

Comparing analyst projections with company financial filings, such as annual 10-K and quarterly 10-Q reports, can provide additional context and help investors evaluate the assumptions underlying a research recommendation.

Ultimately, the strength of an investment thesis depends not only on identifying opportunities but also on understanding what could prevent them from materializing.

Using Equity Research to Identify Investment Opportunities

For investors researching small-cap and microcap companies, access to detailed financial analysis can be especially valuable.

These businesses may operate in emerging industries, specialized markets, or sectors that receive relatively limited attention from larger financial institutions.

Channelchek provides access to equity research published by Noble Capital Markets, alongside company profiles, market news, and investor presentations covering publicly traded companies.

By examining research reports alongside company disclosures and broader market developments, investors can develop a more complete understanding of individual investment opportunities.

Ultimately, evaluating equity research means looking beyond a stock rating or price target to understand the financial fundamentals, valuation assumptions, growth drivers, and risks shaping a company’s outlook.

This article is for informational and educational purposes only and does not constitute personalized investment advice.

Codere Online (CDRO) – Strong Results, More Measured Outlook


Tuesday, November 17, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 Operating Results. The company reported Q3 Gaming Win of €67.1 million, an increase of 30% year-over-year, driven by strong results in Mexico and Spain. Adjusted EBITDA increased 45% to €4.2 million, with margins expanding to 6.3% from 5.6% a year ago. Notably, while results were strong, higher marketing expenditures and gaming taxes impacted profitability in the quarter.

Underlying Business Trends. Mexico Gaming Win increased 39% to €37.2 million, driven by a 43% increase in spending per active player despite a 3% decline in active players. However, segment-adjusted EBITDA declined 15% to €1.7 million, driven by higher marketing and gaming taxes. Spain Gaming Win increased 13% to €24.8 million, while adjusted EBITDA rose 24% to €7.2 million, reflecting stronger operating leverage.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Xcel Brands (XELB) – Revenue Lags Behind New Brand Launches


Tuesday, November 17, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 Results. Xcel reported Q3 revenue of $1.06 million, down 5.2% from $1.12 million in the prior-year period and below our $2.0 million estimate. The adjusted EBITDA loss narrowed to $0.46 million from $0.65 million, with the margin improving to negative 43.4% from negative 58.4%. Lower payroll and corporate overhead supported profitability despite softer revenue.

Legacy Brands Still Dominate. Halston generated $0.64 million in licensing revenue, accounting for roughly 60% of the quarter, while Qurate contributed $0.21 million, or 19%. The Judith Ripka divestiture weighed on comparisons, although contributions from other brands provided a partial offset. Vendor-related shipping delays constrained newer programs, leaving revenue dependent on established relationships as the creator portfolio develops.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.